MuriGenics, Inc. Competitors

At Theragenics, we’re dedicated to empowering the fight against cancer and other diseases by producing innovative medical radioisotopes. These vital materials form the foundation of radiopharmaceuticals and LDR brachytherapy treatments, offering patients minimally invasive and targeted options. Since 1981, we have been at the forefront of radioisotope production, continually pushing boundaries to advance cancer care. Our unwavering dedication to the healthcare community ensures a reliable supply to meet your needs. Through strong partnerships, we strive for optimal patient outcomes. Partner with Theragenics to access the vital radioisotopes vital for life-saving treatments.

Medigene AG (FSE: MDG1) is a leading immuno-oncology platform company dedicated to developing T-cell therapies to effectively eliminate cancer. Its end-to-end technology platform is built on multiple proprietary exclusive product development and product enhancement technologies, and allows Medigene to create best-in-class differentiated, T cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering. For more information, please visit www.medigene.com

NexGen provides a cloud infrastructure that clients utilize to provision a variety of computing resources such as processing and storage. The NexGen infrastructure also provides the facilities, network, and hardware in addition to a selection of infrastructure supported operational software such as, but not limited to, host operating systems, and virtualization software. The NexGen infrastructure is architected, managed, and maintained according to security best practices in combination with a number of security compliance standards. NexGen provides clients with the capacity to host web architectures on some of the most secure computing infrastructure in the world.